1. Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls 
Court Pedersen, M.D., Sc.D., Morten Breindahl, M.D., Ph.D., Naresh Aggarwal, M.B.B.S., C.C.F.P., F.C.F.P., Johan Berglund, M.D., Ph.D., György Oroszlán, M.D., Ph.D., Sven Arne Silfverdal, M.D., Ph.D., M.P.H., Péter Szüts, M.D., Ph.D., Michael O'Mahony, Ph.D., Marie-Pierre David, M.Sc., Kurt Dobbelaere, M.D., Gary Dubin, M.D., Dominique Descamps, M.D. 
Journal of Adolescent Health 
Volume 50, Issue 1, Pages (January 2012)
DOI: /j.jadohealth
Copyright © 2012 Society for Adolescent Health and Medicine Terms and Conditions

2. Figure 1
Participant disposition. HPV group = HPV-16/18 vaccine at months 0, 1, and 6. HAB group = combined hepatitis A and B vaccine at months 0, 1, and 6. HPV + HAB group = HPV-16/18 vaccine coadministered with combined hepatitis A and B vaccine at months 0, 1, and 6.
Journal of Adolescent Health  , 38-46DOI: ( /j.jadohealth )
Copyright © 2012 Society for Adolescent Health and Medicine Terms and Conditions

3. Figure 2
Immune response to HPV-16/18 AS04-adjuvanted vaccine 1 month after the third vaccine dose in initially seronegative subjects by age (according-to-protocol cohort for immunogenicity). HPV group = HPV-16/18 vaccine at months 0, 1, and 6. HPV + HAB group = HPV-16/18 vaccine coadministered with combined hepatitis A and B vaccine at months 0, 1, and 6. Bars show GMT and associated 95% confidence interval. Percentages at base of bars indicate seroconversion rate (initially seronegative subjects with anti-HPV-16 antibody titer ≥8 EL.U/mL or anti-HPV-18 antibody titer ≥7 EL.U/mL at month 7). Numbers above bars indicate GMT value.
Journal of Adolescent Health  , 38-46DOI: ( /j.jadohealth )
Copyright © 2012 Society for Adolescent Health and Medicine Terms and Conditions